Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: alcaftadine

« Back to Dashboard
Alcaftadine is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has seventy-five patent family members in forty countries.

There are five drug master file entries for alcaftadine. Three suppliers are listed for this compound.

Summary for Generic Name: alcaftadine

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Suppliers / Packaging: see list4

Clinical Trials for: alcaftadine

Ocular Allergy Treatment Practical Impact Trial
Status: Recruiting Condition: Allergic Conjunctivitis; Rhinoconjunctivitis

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Status: Completed Condition: Conjunctivitis, Allergic

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Status: Completed Condition: Conjunctivitis, Allergic

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Status: Active, not recruiting Condition: Allergic Conjunctivitis

A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
Status: Recruiting Condition: Allergic Conjunctivitis

Safety and Efficacy Study of a Eye Drop for Eye Allergy
Status: Completed Condition: Allergic Conjunctivitis

Comparison of Tolerability Between Two Allergy Drops
Status: Enrolling by invitation Condition: Allergic Conjunctivitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes8,664,215<disabled><disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes<disabled><disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes5,468,743<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: alcaftadine

Country Document Number Publication Date
China1068118Jan 20, 1993
Singapore170044Apr 29, 2011
Taiwan201446249Dec 16, 2014
Poland170776Jan 31, 1997
JapanH06507889Sep 08, 1994
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc